1h Free Analyst Time
Muscarinic Acetylcholine Receptor M2 (CHRM2) pipeline Target constitutes close to 10 molecules. Out of which approximately 10 molecules are developed by Companies. The latest report Muscarinic Acetylcholine Receptor M2 - Drugs In Development, 2022, outlays comprehensive information on the Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.Speak directly to the analyst to clarify any post sales queries you may have.
Muscarinic Acetylcholine Receptor M2 (CHRM2) - Muscarinic cholinergic receptor 2 is an acetylcholine receptor. It is expressed in various regions of the brain including the cerebellum, cerebral cortex, hippocampus, medulla, striatum, and thalamus, and in lung and prostate. It mediates smooth muscle contractility. Increase in M2 receptor has been associated with depression. The molecules developed by companies in Filing rejected/Withdrawn, Phase III, Phase II and Preclinical stages are 1, 2, 5 and 2 respectively.
Report covers products from therapy areas Central Nervous System, Respiratory, Genito Urinary System And Sex Hormones, Cardiovascular, Dermatology, Genetic Disorders and Undisclosed which include indications Alzheimer's Disease, Obstructive Sleep Apnea, Overactive Bladder, Parkinson's Disease, Angelman Syndrome, Axillary Hyperhidrosis, Depression, Fragile X Syndrome, Infantile Spasm (West Syndrome), Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome), Psychosis, Rett Syndrome, Schizophrenia, Snoring, Stroke, Tuberous Sclerosis, Unspecified Rare Disease and Urinary Incontinence.
Furthermore, this report also reviews key players involved in Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Muscarinic Acetylcholine Receptor M2 (CHRM2)
- The report reviews Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Muscarinic Acetylcholine Receptor M2 (CHRM2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Muscarinic Acetylcholine Receptor M2 (CHRM2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of TablesList of Figures
Introduction
Report Coverage
Muscarinic Acetylcholine Receptor M2 (CHRM2) - Overview
Muscarinic Acetylcholine Receptor M2 (CHRM2) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Muscarinic Acetylcholine Receptor M2 (CHRM2) - Companies Involved in Therapeutics Development
Anavex Life Sciences Corp
Apnimed Inc
Dermavant Sciences Inc
Karuna Therapeutics Inc
Sinsin Pharmaceutical Co Ltd
TheraVida Inc
Trigone Pharma Ltd
Muscarinic Acetylcholine Receptor M2 (CHRM2) - Drug Profiles
(atomoxetine + oxybutynin) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(lidocaine + oxybutynin) SR - Drug Profile
Product Description
Mechanism Of Action
History of Events
(oxybutynin + pilocarpine) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(oxybutynin + reboxetine) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(pilocarpine + tolterodine) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(trospium chloride + xanomeline) - Drug Profile
Product Description
Mechanism Of Action
History of Events
AD-109 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ANAVEX-141 - Drug Profile
Product Description
Mechanism Of Action
History of Events
blarcamesine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
oxybutynin - Drug Profile
Product Description
Mechanism Of Action
Muscarinic Acetylcholine Receptor M2 (CHRM2) - Dormant Products
Muscarinic Acetylcholine Receptor M2 (CHRM2) - Discontinued Products
Muscarinic Acetylcholine Receptor M2 (CHRM2) - Product Development Milestones
Featured News
May 18, 2022: Karuna Therapeutics to host virtual event highlighting clinical program for psychosis in Alzheimer’s disease
Mar 15, 2022: Anavex Life Sciences announces presentation of phase 2 clinical biomarker data from Anavex 2-73-PDD-001 Parkinson’s disease dementia study at AD/PD™ 2022 International Conference
Mar 09, 2022: Apnimed study APC-004 phase 2 data to be presented at World Sleep 2022
Feb 04, 2022: Anavex life sciences provides supplemental information on ANAVEX 2-73 (blarcamesine) AVATAR Phase 3 trial for the treatment of adult patients with Rett syndrome
Feb 01, 2022: ANAVEX 2-73 (Blarcamesine) AVATAR phase 3 trial met primary and secondary efficacy endpoints
Dec 16, 2021: Apnimed announces dosing of first patient in phase 3 MARIPOSA confirmatory trial of AD504, a potential nighttime oral treatment for Obstructive Sleep Apnea (OSA)
Oct 13, 2021: Anavex Life Sciences reports data review by the independent DSMB reported for phase 2b/3 trial of ANAVEX 2-73 for AD
Oct 13, 2021: Apnimed announces positive phase 2 (Study APC-003) data demonstrating durability-of-effect and improved quality-of-life in patients with obstructive sleep apnea after investigational AD109 treatment
Oct 13, 2021: Apnimed announces positive phase 2 data (Study APC-004) demonstrating improvement in measures of obstructive sleep apnea and a dose-response with AD109, an oral pharmacologic investigational treatment for the disease
Sep 13, 2021: Novamind to serve as research site for Karuna Therapeutics late-stage clinical trial
Aug 26, 2021: Anavex Life Sciences announces publication of Foundational data for ANAVEX2-73 (blarcamesine) in Fragile X syndrome (Autism)
Aug 13, 2021: Trigone Pharma announces the initiation of a phase 2 clinical trial of TRG-100 in patients with interstitial cystitis/bladder pain syndrome
Jul 29, 2021: Anavex Life Sciences announces ANAVEX2-73 (Blarcamesine) significantly prevented Aß (Abeta)-induced cognitive deficits with Confirmed Significant Biomarker-response in Animal Model of Alzheimer’s Disease
Jul 22, 2021: Trigone Pharma to present preclinical data for TRG-100 in interstitial cystitis / bladder pain syndrome at the upcoming American Urological Association Conference (AUA) in September 2021
Jun 29, 2021: Anavex reports positive data from Parkinson’s disease dementia study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
- Number of - Products under Development by Stage of Development, 2022
- Number of - Products under Development by Therapy Areas, 2022
- Number of - Products under Development by Indication, 2022
- Number of - Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Products under Development by Companies, 2022 (Contd..1)
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by Anavex Life Sciences Corp, 2022
- Pipeline by Apnimed Inc, 2022
- Pipeline by Dermavant Sciences Inc, 2022
- Pipeline by Karuna Therapeutics Inc, 2022
- Pipeline by Sinsin Pharmaceutical Co Ltd, 2022
- Pipeline by TheraVida Inc, 2022
- Pipeline by Trigone Pharma Ltd, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022
List of Figures
- Number of - Products under Development by Stage of Development, 2022
- Number of - Products under Development by Therapy Areas, 2022
- Number of - Products under Development by Top 10 Indications, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Anavex Life Sciences Corp
- Apnimed Inc
- Dermavant Sciences Inc
- Karuna Therapeutics Inc
- Sinsin Pharmaceutical Co Ltd
- TheraVida Inc
- Trigone Pharma Ltd
